“DLK1 is a therapeutic target in MPNST, and its expression can be
modulated by epigenetic modifications”
Categories
George Annor, Ph.D, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute [Video]
“DLK1 is a therapeutic target in MPNST, and its expression can be
modulated by epigenetic modifications”